A Open Label Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression
This study is currently recruiting participants.
Verified October 2012 by Jonsson Comprehensive Cancer Center
Study NCT01536743
Information provided by Jonsson Comprehensive Cancer Center
First Received on December 1, 2011.
Last Updated on October 2, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
